

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

Examiner: Carlos A. Azpuru

Wouter E. Roorda et al.

Serial No.: 10/693,047

Art Unit: 1615

Filed: October 24, 2003

Title: PERMEABILIZING REAGENTS TO INCREASE DRUG DELIVERY
AND A METHOD OF LOCAL DELIVERY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

Dear Examiner Azpuru:

Enclosed is the signed Declaration of Wouter E. Roorda. The unsigned Declaration was submitted with our Response dated October 5, 2004.


If the Examiner has any questions or concerns, the Examiner is invited to telephone the undersigned attorney at (415) 954-0345.


Date: November 3, 2004

Respectfully submitted,

Squire, Sanders & Dempsey LLP
One Maritime Plaza, Suite 300
San Francisco, CA 94111-3492

Telephone: 415-954-0345


Brian S. Boyer for
Paul J. Meyer, Jr.
Reg. No. 47,791
Attorney for Applicants

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Examiner: Carlos A. Azpuru

Wouter E. Roorda et al.

Serial No.: 10/693,047

Art Unit: 1615

Filed: October 24, 2003

Title: PERMEABILIZING REAGENTS TO INCREASE DRUG DELIVERY
AND A METHOD OF LOCAL DELIVERY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**DECLARATION UNDER 37 CFR § 1.131**


I, Wouter E. Roorda, declare as follows:

1. I conceived of or invented the subject matter of at least independent Claims 12 and 19 as originally filed in the application identified above. I conceived of or invented such subject matter prior to June 8, 2000.
2. I have attached a redacted copy of an invention disclosure form showing the subject matter of the invention as embodied by at least Claims 12 and 19. As can be seen, this selection of pages shows conception of the subject matter of Claims 12 and 19 prior to June 8, 2000.
3. The subject matter of the invention was reduced to practice in a diligent manner, as at least shown by the constructive reduction to practice of the invention merely seventeen (17) months after the filing date of the Walsh reference (U.S. Patent No. 6,689,807). In particular, the filing date of the Walsh reference was June 8, 2000, while the filing date of the parent for the current application was November 30, 2001.

4. I further declare that all statements made herein of my own knowledge are true and that all statements made upon information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Executed at Santa Clara, California on this 22 day of October __, 2004.

Squire, Sanders & Dempsey L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111-3492
Telephone (415) 954-0345
Facsimile (415) 393-9887

By: 
Wouter E. Roorda
Employee of
Advanced Cardiovascular Systems, Inc.

header not part of original

Appendix

header not part of original

REDACTED

REDACTED

ADVANCED CARDIOVASCULAR SYSTEMS, INC.

REDACTED

REDACTED

INVENTION DISCLOSURE FORM

REDACTED

1. DESCRIPTIVE TITLE OF THE INVENTION

Use of permeation enhancers in local intravascular drug delivery

2. DESCRIPTION AND USE

REDACTED

The local uptake of drugs after localized delivery in the vasculature tends to be very low. Part of the reason for this is the limited permeability of the vessel wall. In general, drugs absorbed in the wall of a blood vessel pass through cells and cell membranes rather than between cells. An exception are capillary vessels, which tend to have open pores between their endothelial cells. Therefore, creating channels between cells, or increasing the permeability of cell membranes may lead to increased uptake of drugs that have been delivered to the lumen of the vessel.

Opening channels between cells may be possible by osmotically shocking the tissue. This method has been applied with some success in capillaries of the brain, where tight junctions between cells

header not part of original

REDACTED

provide a barrier known as the blood-brain barrier. In the application described in this disclosure the osmotic agent, e.g. a sugar solution, can be delivered together with, or just before administration of the drug. The effect of the hyperosmotic sugar solution is to rapidly, but transiently dehydrate cells at the surface of the vessel. This leads to temporary shrinkage of the cells, and exposes underlying tissue to the drug solution.

Alternatively, Ca-ion chelating compounds have been used to open up tight junctions between cells, and may be used to increase the permeability of the endothelial lining of blood vessels. Other compounds, like sodium salicylate and taurodiethyldisulfate may serve the same purpose.

Another method is to use surfactant-like molecules that insert themselves into cell membranes and effectively disrupt the dense structure of these membranes. The greater fluidity of the membranes allows for a more rapid permeation of drug molecules, and enhances their uptake into the cells. This type of compounds includes many non-ionic surfactants, like partially hydrolyzed triglycerides, fatty-acid sugar derivatives, oleic acid derivatives etc.

Finally Receptor Mediated Permeation enhancers may be used. This is another approach that has worked to some extent in efforts to pass the blood-brain barrier. These peptide-like molecules activate certain receptor mediated absorption mechanisms. Examples are bradykinin and some of its derivatives.




This disclosure describes methods to improve the local absorption of drugs after intravascular delivery by using of compounds that increase the permeability of the tissue lining the inner wall of a blood vessel.

REDACTED


This invention can potentially be used in conjunction with any type of local intravascular drug delivery.

REDACTED

" " header not part of original



header not part of original





Read and Understood the completed Invention Disclosure Form (not a Submitter)



0/3/99
Date

A handwritten signature in black ink, appearing to be "ECC" followed by a stylized flourish.





Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/693,047	
	Filing Date	October 24, 2003	
	First Named Inventor	Wouter E. Roorda et al.	
	Group Art Unit	1615	
	Examiner Name	Carlos A. Azpuru	
Total Number of Pages in This Submission (excluding references)	9	Attorney Docket Number	50623.00349

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Deposit Account 07-1850 Authorization	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Postage Paid Return Postcard	<input type="checkbox"/> Drawing(s) In/Formal ____ Sheets with Submission of Drawings Transmittal	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Amendment Transmittal Letter (in duplicate)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Declaration of Wouter E. Roorda (7 pages)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Petition for Extension of Time (____ months) (in duplicate)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Information Disclosure Statement (in duplicate) with Form PTO-1449	<input type="checkbox"/> Terminal Disclaimer	Communication (1 page)
<input checked="" type="checkbox"/> Express Mail Label No. EV 337 976 891 US	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) ____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Brian S. Boyer, Ph. D., Reg. No. 52,643
Signature	
Date	November 3, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: November 3, 2004			
Typed or printed name	Patricia Gamble		
Signature		Date	November 3, 2004

Burden Hour Statement: This form is estimated to take 02 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.